Are Analysts Bullish about Mylan N.V. (NASDAQ:MYL) after last week?

Mylan N.V. (NASDAQ:MYL) Logo
Investors sentiment increased to Infinity in Q1 2019. Its up Infinity, from 0.33 in 2018Q4. It increased, as 0 investors sold Mylan N.V. shares while 0 reduced holdings. 1 funds opened positions while 1 raised stakes. 259,686 shares or 99.91% more from 129,903 shares in 2018Q4 were reported.
Gulf National Bank (Uk) Limited holds 0.06% of its portfolio in Mylan N.V. (NASDAQ:MYL) for 115,438 shares. Gemmer Asset Management Llc invested in 0% or 91 shares.

Mylan N.V. (NASDAQ:MYL) Ratings Coverage

Among 13 analysts covering Mylan Inc (NASDAQ:MYL), 9 have Buy rating, 0 Sell and 4 Hold. Therefore 69% are positive. Mylan Inc had 18 analyst reports since February 26, 2019 according to SRatingsIntel. RBC Capital Markets maintained the shares of MYL in report on Wednesday, February 27 with “Buy” rating. The rating was maintained by BTIG Research on Wednesday, February 27 with “Buy”. The firm earned “Buy” rating on Wednesday, February 27 by J.P. Morgan. SunTrust initiated Mylan N.V. (NASDAQ:MYL) on Tuesday, March 19 with “Buy” rating. The rating was downgraded by Wells Fargo on Wednesday, May 8 to “Market Perform”. The firm earned “Buy” rating on Wednesday, February 27 by BMO Capital Markets. Cowen & Co maintained the shares of MYL in report on Wednesday, February 27 with “Hold” rating. The firm has “Overweight” rating given on Tuesday, July 30 by Morgan Stanley. The rating was maintained by Raymond James on Wednesday, February 27 with “Buy”. As per Wednesday, March 6, the company rating was upgraded by Morgan Stanley. Below is a list of Mylan N.V. (NASDAQ:MYL) latest ratings and price target changes.

30/07/2019 Broker: Morgan Stanley Rating: Overweight Old Target: $22.0000 New Target: $25.0000 Maintain
11/06/2019 Broker: Barclays Capital Rating: Overweight New Target: $26.0000 Initiates Coverage On
21/05/2019 Broker: BidaskScore Rating: Sell Downgrade
08/05/2019 Broker: Wells Fargo Old Rating: Outperform New Rating: Market Perform Old Target: $33.0000 New Target: $22.0000 Downgrade
30/04/2019 Broker: BidaskScore Rating: Sell Upgrade
19/03/2019 Broker: SunTrust Rating: Buy New Target: $35 Initiate
06/03/2019 Broker: Credit Suisse Rating: Buy New Target: $37 Maintain
06/03/2019 Broker: Morgan Stanley Old Rating: Equal-Weight New Rating: Overweight New Target: $35 Upgrade
27/02/2019 Broker: Mizuho Rating: Hold New Target: $32 Maintain
27/02/2019 Broker: J.P. Morgan Rating: Buy New Target: $39 Maintain

The stock increased 3.08% or $0.59 during the last trading session, reaching $19.72. About 4.97M shares traded. Mylan N.V. (NASDAQ:MYL) has declined 42.99% since August 13, 2018 and is downtrending. It has underperformed by 42.99% the S&P500.

Mylan N.V., together with its subsidiaries, develops, licenses, makes, markets, and distributes generic, brand name, and over-the-counter products worldwide. The company has market cap of $10.17 billion. The firm operates through three divisions: North America, Europe, and Rest of World. It has a 323.28 P/E ratio. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.

More notable recent Mylan N.V. (NASDAQ:MYL) news were published by: which released: “Mapi Pharma to Build a New Sterile Injectable Production Plant for GA Depot in Jerusalem – Nasdaq” on July 15, 2019, also with their article: “The Vanguard Health Care Fund Buys Pfizer, Humana – Yahoo Finance” published on August 05, 2019, published: “Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger – Nasdaq” on August 02, 2019. More interesting news about Mylan N.V. (NASDAQ:MYL) were released by: and their article: “Noteworthy Wednesday Option Activity: MU, ADBE, MYL – Nasdaq” published on July 24, 2019 as well as‘s news article titled: “Mylan-Pfizer Deal: MYL Stock Soars on Off-Patent Drug Merger – Nasdaq” with publication date: July 29, 2019.

Mylan N.V. (NASDAQ:MYL) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.